| First Author | Yu H | Year | 2022 |
| Journal | MedComm (2020) | Volume | 3 |
| Issue | 4 | Pages | e180 |
| PubMed ID | 36254251 | Mgi Jnum | J:352636 |
| Mgi Id | MGI:7663157 | Doi | 10.1002/mco2.180 |
| Citation | Yu H, et al. (2022) Integrated analyses of brain and platelet omics reveal their common altered and driven molecules in Alzheimer's disease. MedComm (2020) 3(4):e180 |
| abstractText | Platelets may serve as a perfect peripheral source for exploring diagnostic biomarkers for Alzheimer's disease (AD); however, the molecular linkage between platelet and the brain is missing. To find the common altered and driving molecules in both brain and the platelet, we performed an integrated analysis of our platelet omics and brain omics reported in the literature, and analyzed their correlations with AD-specific pathology and cognitive impairment. By integrating the gene and protein expression profiles from 269 AD patients, we deduced 239 differentially expressed proteins (DEPs) appeared in both brain and the platelet, and 70.3% of them had consistent changes. Further analysis demonstrated that the altered brain and peripheral regulations were pinpointed into 10 imbalanced pathways. We also found that 117 DEPs, including ADAM10, were closely associated to the AD-specific beta-amyloid and tau pathologies; and the changes of IDH3B and RTN1 had a potential diagnostic value for cognitive impairment analyzed by machine learning. Finally, we identified that HMOX2 and SERPINA3 could serve as driving molecules in neurodegeneration, and they were increased and decreased in AD patients, respectively. Together, this integrated brain and platelet omics provides a valuable resource for establishing efficient peripheral diagnostic biomarkers and potential therapeutic targets for AD. |
